Protara Therapeutics Statistics
Share Statistics
Protara Therapeutics has 20.63M shares outstanding. The number of shares has increased by 81.52% in one year.
| Shares Outstanding | 20.63M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.19% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 18.41M |
| Failed to Deliver (FTD) Shares | 11.44K |
| FTD / Avg. Volume | 0.53% |
Short Selling Information
The latest short interest is 2.74M, so 13.27% of the outstanding shares have been sold short.
| Short Interest | 2.74M |
| Short % of Shares Out | 13.27% |
| Short % of Float | 14.87% |
| Short Ratio (days to cover) | 14.46 |
Valuation Ratios
The PE ratio is -0.53 and the forward PE ratio is -0.84.
| PE Ratio | -0.53 |
| Forward PE | -0.84 |
| PS Ratio | 0 |
| Forward PS | 4.8 |
| PB Ratio | 0.31 |
| P/FCF Ratio | -0.57 |
| PEG Ratio | n/a |
Enterprise Valuation
Protara Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 11.17, with a Debt / Equity ratio of 0.01.
| Current Ratio | 11.17 |
| Quick Ratio | 11.17 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 1.42 |
| Cash Flow / Debt | -38.21 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.59% and return on capital (ROIC) is -59.11%.
| Return on Equity (ROE) | -0.59% |
| Return on Assets (ROA) | -0.51% |
| Return on Capital (ROIC) | -59.11% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.55M |
| Employee Count | 26 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 221.91% in the last 52 weeks. The beta is 1.79, so Protara Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.79 |
| 52-Week Price Change | 221.91% |
| 50-Day Moving Average | 2.77 |
| 200-Day Moving Average | 2.7 |
| Relative Strength Index (RSI) | 79.27 |
| Average Volume (20 Days) | 2.16M |
Income Statement
In the last 12 months, Protara Therapeutics had revenue of $0 and earned -$40.42M in profits. Earnings per share was $-3.57.
| Revenue | 0 |
| Gross Profit | -341.00K |
| Operating Income | -43.61M |
| Net Income | -40.42M |
| EBITDA | -43.27M |
| EBIT | - |
| Earnings Per Share (EPS) | -3.57 |
Balance Sheet
The company has $39.59M in cash and $5.47M in debt, giving a net cash position of $34.12M.
| Cash & Cash Equivalents | 39.59M |
| Total Debt | 5.47M |
| Net Cash | 34.12M |
| Retained Earnings | -200.38M |
| Total Assets | 94.09M |
| Working Capital | 76.44M |
Cash Flow
In the last 12 months, operating cash flow was -$37.56M and capital expenditures -$45.00K, giving a free cash flow of -$37.60M.
| Operating Cash Flow | -37.56M |
| Capital Expenditures | -45.00K |
| Free Cash Flow | -37.60M |
| FCF Per Share | -3.32 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
TARA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -62.3% |
| FCF Yield | -31.81% |
Analyst Forecast
The average price target for TARA is $23, which is 301.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $23 |
| Price Target Difference | 301.4% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Jan 10, 2020. It was a backward split with a ratio of 1:40.
| Last Split Date | Jan 10, 2020 |
| Split Type | backward |
| Split Ratio | 1:40 |
Scores
| Altman Z-Score | 2.21 |
| Piotroski F-Score | 2 |